Overview

This trial is active, not recruiting.

Condition urothelial cancer
Treatment pembrolizumab
Phase phase 2
Target PD-1
Sponsor Merck Sharp & Dohme Corp.
Start date February 2015
End date June 2018
Trial size 350 participants
Trial identifier NCT02335424, 2014-002206-20, 3475-052

Summary

This is a study using pembrolizumab (MK-3475, KEYTRUDA®) for first-line treatment of participants with advanced/unresectable (inoperable) or metastatic urothelial cancer who are ineligible for cisplatin-based therapy. The primary study objective is to determine the objective response rate (ORR) in all participants, in participants whose tumors rely on programmed cell death ligand 1 (PD-L1) protein (PD-L1-positive tumors), and in participants with strongly PD-L1-positive tumors.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Participants receive pembrolizumab, 200 mg intravenous (IV) on Day 1 of each 3-week cycle for up to 24 months
pembrolizumab MK-3475
IV infusion

Primary Outcomes

Measure
ORR by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) for All Participants (Independent Radiology Review)
time frame: Up to 3 years
ORR by RECIST 1.1 for Participants with PD-L1-positive Tumors (Independent Radiology Review)
time frame: Up to 3 years
ORR by RECIST 1.1 for Participants with Strongly PD-L1-positive Tumors (Independent Radiology Review)
time frame: Up to 3 years

Secondary Outcomes

Measure
Duration of Response (DOR) by RECIST 1.1 for All Participants, Participants with PD-L1-positive Tumors and Participants with Strongly PD-L1-positive Tumors (Independent Radiology Review)
time frame: Up to 3 years
Progression-free Survival (PFS) by RECIST 1.1 for All Participants, Participants with PD-L1-positive Tumors and Participants with Strongly PD-L1-positive Tumors (Independent Radiology Review)
time frame: Up to 3 years
Overall Survival (OS) for All Participants, Participants with PD-L1-positive Tumors and Participants with Strongly PD-L1-positive Tumors
time frame: Up to 3 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Histologically- or cytologically-confirmed diagnosis of advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra (transitional cell and mixed transitional/non-transitional cell histologies) - Ineligible for cisplatin therapy - No prior systemic chemotherapy for metastatic disease (adjuvant or neoadjuvant platinum-based chemotherapy with recurrence >12 months since completion of therapy is allowed) - Available tissue from a newly obtained core or excisional biopsy of a tumor lesion not previously irradiated - Measureable disease - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 - Adequate organ function - Female participants of childbearing potential have a negative urine or serum pregnancy test; surgically sterile, or willing to use 2 acceptable methods of birth control, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study treatment - Male participants must be willing to use an adequate method of contraception starting with the first dose of study medication through 120 days after the last dose of study treatment Exclusion Criteria: - Disease that is suitable for local therapy administered with curative intent - Currently participating or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study treatment - Prior anti-cancer monoclonal antibody (mAb) for direct anti-neoplastic treatment within 4 weeks prior to study Day 1 or who has not recovered from adverse events due to agents administered more than 4 weeks earlier - Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not recovered from AEs due to a previously administered agent - Known additional malignancy that is progressing or requires active treatment excepting basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cancer - Known active central nervous system (CNS) metastases and/or carcinomatous meningitis - Active autoimmune disease that has required systemic treatment in past 2 years - Evidence of interstitial lung disease or active non-infectious pneumonitis - Active infection requiring systemic therapy - Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of study treatment - Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another co-inhibitory T-cell receptor - Known human immunodeficiency virus (HIV) - Known active Hepatitis B or C - Received a live virus vaccine within 30 days of planned start of study treatment

Additional Information

Official title A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer
Description Participants receiving pembrolizumab who attain a complete response (CR) may consider stopping trial treatment if they meet criteria for holding therapy. Participants who stop trial treatment after receiving 24 months of trial treatment for reasons other than progressive disease (PD) or intolerability, or participants who attain a CR and stop trial treatment may be eligible for up to one year of retreatment upon experiencing PD.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Merck Sharp & Dohme Corp..